2024
Net Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty
Yaesoubi R, Kunst N. Net Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty. Medical Decision Making 2024, 44: 770-786. PMID: 39056310, DOI: 10.1177/0272989x241262343.Peer-Reviewed Original ResearchResults of cost-effectiveness analysesNet monetary benefitCost-effectiveness planeCost-effectiveness analysisMonetary benefitsDecision uncertaintyDecision problemEffect estimatesHypothetical decision problemResults of economic evaluationsValue-of-informationDecision makersCost-effectiveness ratioEconomic evaluation studiesCorrelated costsHigh varianceLevel of uncertaintyParameter uncertaintiesEconomic evaluationMagnitude of parametersMakersDecisionUncertaintyCostMonetaryAssessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis
Yin X, Li Y, Rönn M, Li S, Yuan Y, Gift T, Hsu K, Salomon J, Grad Y, Yaesoubi R. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine 2024, 21: e1004424. PMID: 38976754, PMCID: PMC11262662, DOI: 10.1371/journal.pmed.1004424.Peer-Reviewed Original ResearchDrug susceptibility testingQuality-adjusted life yearsFirst-line therapyFirst-line antibioticsNet health benefitFirst-lineRetreatment regimensResistance prevalenceRapid drug susceptibility testingRate of treatment failureTreatment of gonorrheaIncidence of gonorrheaAssociated with gonorrheaEmpirical therapyTreatment failureEmpirical treatmentGonococcal infectionSusceptibility testingGonorrhea casesMSM populationGonorrheaCost-effectiveness analysisDiagnostic testsResistant strainsTherapyHow many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses?
Yaesoubi R. How many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses? Value In Health 2024, 27: 1553-1563. PMID: 38977192, DOI: 10.1016/j.jval.2024.06.016.Peer-Reviewed Original ResearchProbabilistic sensitivity analysesIncremental cost-effectiveness ratioProbabilistic cost-effectiveness analysisCost-effectiveness analysisEstimate incremental cost-effectiveness ratiosIncremental cost-effectiveness ratio estimatesCost-effectiveness ratioDecision optionsStochastic modelPresence of parameter uncertaintiesCostParameter uncertaintiesUncertaintyLevel of accuracyInequalitySensitivity analysisEstimationMonteModelMonte Carlo samplingParameter samplesChebyshev inequality
2023
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitionsThe Estimated Lifetime Quality-Adjusted Life-Years Lost Due to Chlamydia, Gonorrhea, and Trichomoniasis in the United States in 2018
Li Y, You S, Lee K, Yaesoubi R, Hsu K, Gift T, Chesson H, Berruti A, Salomon J, Rönn M. The Estimated Lifetime Quality-Adjusted Life-Years Lost Due to Chlamydia, Gonorrhea, and Trichomoniasis in the United States in 2018. The Journal Of Infectious Diseases 2023, 227: 1007-1018. PMID: 36806950, PMCID: PMC10112678, DOI: 10.1093/infdis/jiad047.Peer-Reviewed Original ResearchConceptsLifetime QALYsSubstantial health lossesDuration of infectionCost-effectiveness analysisGenital chlamydiaInfection interventionTotal QALYsIncident infectionsChronic sequelaeInfection helpGonorrheaAge groupsChlamydiaInfectionMultivariate sensitivity analysisHealth lossTrichomoniasisQALYWomenSequelaeUnited StatesPrevention policiesQALYsPopulation levelLifetime quality
2022
Estimation of the Lifetime Quality-Adjusted Life Years (QALYs) Lost Due to Syphilis Acquired in the United States in 2018
Lee K, You S, Li Y, Chesson H, Gift TL, Berruti AA, Hsu K, Yaesoubi R, Salomon JA, Rönn M. Estimation of the Lifetime Quality-Adjusted Life Years (QALYs) Lost Due to Syphilis Acquired in the United States in 2018. Clinical Infectious Diseases 2022, 76: e810-e819. PMID: 35684943, PMCID: PMC9907519, DOI: 10.1093/cid/ciac427.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCongenital syphilisHealth lossLife yearsNumber of QALYsTerms of QALYsLifetime numberBurden of syphilisSubstantial health lossesManagement of syphilisLifetime quality-adjusted life yearsAverage lifetime numberCost-effectiveness analysisPrimary infectionOverall burdenSyphilisNatural historyInfectionHealth impactsMSMChildrenMothersUnited StatesBurdenDecision tree model
2018
A Cost-Effectiveness Analysis of a Pediatric Operating Room in Uganda
Yap A, Muzira A, Cheung M, Healy J, Kakembo N, Kisa P, Cunningham D, Youngson G, Sekabira J, Yaesoubi R, Ozgediz D. A Cost-Effectiveness Analysis of a Pediatric Operating Room in Uganda. Surgery 2018, 164: 953-959. PMID: 29801729, PMCID: PMC6399742, DOI: 10.1016/j.surg.2018.03.023.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCost-Benefit AnalysisDecision Making, OrganizationalDecision TreesFemaleHealth Services AccessibilityHealth Services Needs and DemandHumansInfantInfant, NewbornLife ExpectancyMaleModels, EconomicMonte Carlo MethodOperating RoomsQuality-Adjusted Life YearsSurgical Procedures, OperativeTreatment OutcomeUgandaConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness ratioPediatric operating roomDisability-adjusted life-year avertedStatistical life approachNet economic benefitsCost-effectiveness thresholdLife-year avertedCost-effectiveness analysisAverage life expectancySub-Saharan AfricaMonetary benefitsSensitivity analysisWorthwhile investmentEconomic benefitsOne-wayLow-income settingsTree templatePediatric surgical capacityLife approachFuture decisionsLife expectancyCostInvestment